Upcoming MHRA Meeting Set to Define Preclinical and Early Stage Clinical Development Pathways PR Newswire MELBOURNE, Australia, March 21, 2016 MELBOURNE, Australia, March 21, 2016 /PRNewswire/ — Propanc Health Group Corporation (OTCQB: PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the Company received $1.2 million from an institutional investor in order to fast track itsRead more
- Co-Diagnostics, Inc. Announces Construction Update at JV Manufacturing Facility in India
- Cannabis Strategic Files Provision Patent for Unique Cannabis Smoke Filtration Device
- Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with CellBridge Incorporated
- Pura Naturals Launches New Line of Health and Beauty Products with CBD and Hemp Seed Oils
- Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with 48Hour Discovery
SMALL CAP MARKET NEWS
We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.
LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!
Stock Investors · Accredited Investors · Hedge Fund InvestorsLearn More